Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15653809 | 0.87 | TAAR1 (0.44) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL24686248 | 0.83 | TAAR1 (0.61) | TAAR1SMN1; SMN2CYP1A2LMNAGAA | |
| SCHEMBL14567074 | 0.83 | TAAR1 (0.41) | TAAR1AKR1B1SMN1; SMN2LMNAGAA | |
| SCHEMBL15653271 | 0.81 | TAAR1 (0.40) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL15653808 | 0.79 | TAAR1 (0.39) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL15653270 | 0.79 | AKR1B1 (0.41) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL15652438 | 0.79 | TAAR1 (0.39) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL24093968 | 0.78 | TAAR1 (0.58) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL15654617 | 0.78 | ALDH1A1 (0.45) | TAAR1AKR1B1SMN1; SMN2LMNATSHR | |
| SCHEMBL15652437 | 0.78 | TAAR1 (0.38) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483332-B | Method for preparing 2, 6-dichlorobenzonitrile by 2, 6-dichlorobenzylamino iodination method | 南京工业大学 | 2022-07-05 | — | — | CN | claimed |
| EP-3668880-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-108046978-B | Method for preparing benzyl iodide and derivatives thereof | 云南民族大学 | 2020-05-19 | — | — | CN | disclosed |
| US-20190255009-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | OZCHELA INC (KR) | 2019-08-22 | — | — | US | disclosed |
| WO-2019034725-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-21 | — | — | WO | disclosed |
| EP-3050882-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2545045-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2615085-B1 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMA (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2615085-A1 | Pyridyl derivatives as CFTR modulators | Vertex Pharmaceuticals Incorporated (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6420522-B1 | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-16 | — | — | US | disclosed |
| US-6103711-A | INTERLEUKIN-1 MEDIATED DISEASES; ANTIINFLAMMATORY AND -CARCINOGENIC AGENTS; AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-08-15 | — | — | US | disclosed |
| US-5973111-A | NOVEL COMPOUNDS THAT ARE CAPABLE OF BINDING TO THE ACTIVE SITE OF INTERLEUKIN-1B-CONVERTING ENZYME (ICE) AND INHIBITING ACTIVITY OF THAT ENZYME; ADMINISTERING TO TREAT INFLAMMATORY, AUTOIMMUNE, AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| CN-1159196-A | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255009-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | HPN, P4HB, FKBP1B | TAAR1 3820/4885AKR1B1 92/4885SMN1; SMN2 1141/4885 |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | TAAR1 4377/4885AKR1B1 335/4885SMN1; SMN2 1425/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | TAAR1 4402/4885AKR1B1 330/4885SMN1; SMN2 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.